Combined-modality therapy of rectal cancer with oxaliplatin-based regimens

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 1, 2004, Pages

  Minsky, Bruce D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Clinical assessment; Multimodality therapy; Preoperative therapy; Radiation therapy; Sphincter preservation

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; NEW DRUG; OXALIPLATIN; RALTITREXED; TEGAFUR; UFT;

BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG FATALITY; DRUG INFUSION; HUMAN; INTERMETHOD COMPARISON; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PELVIS; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PROCTITIS; RECTUM CANCER; REVIEW; SKIN TOXICITY;

EID: 3042810130     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.005     Document Type: Article

References (86)

1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444-1450.
2. Skibber JM, Hoff PM, Minsky BD. Cancer of the Rectum. In: De-Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001:1271-1318.
3. Bosset JF, Horiot JC, Hamers HP, et al. Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 2001;61:7-13.
4. Lee JHL, Lee JH, Ahn JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A preliminary report. J Clin Ocol 2002; 20:1751-1758.
5. O'Connell MJ, Martenson JA, Weiand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502-507.
6. Smalley SR, Benedetti J, Williamson S, et al. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT + PVI vs. bolus 5-FU + leucovorin (LV) + Levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc Am Soc Clin Oncol 2003; 22:251 (Abstract #1006).
7. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex local control - final report of Intergroup 0114. J Clin Oncol 2002; 20:1744-1750.
8. Minsky BD, Cohen AM, Enker WE, et al. Combined modality therapy of rectal cancer: Decreased acute toxicity with the pre-operative approach. J Clin Oncol 1992; 10:1218-1224.
9. Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998; 42:51-57.
10. Sauer R. Adjuvant versus neoadjuvant combined modality therapy for locally advaced rectal cancer: first results of the German Rectal Cancer Study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 2003; 57:S124.
11. Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0 rectal cancer. Do all patients require post-operative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42:167-173.
12. Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3:642-647.
13. Colon and Rectum. In: Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002:113-124
14. Gunderson LL, Sargent D, Tepper J, et al. Impact of TN stage and treament on survival and relapse in adjuvant rectal cancer pooled analysis. Proc Am Soc Clin Oncol 2003; 22:251 (Abstract #1008).
15. Green FL, Stewart AK, Norton HJ, A new TNM staging strategy for node-positive (stage III) rectal cancer: an analysis of 5998 patients. Proc Am Soc Clin Oncol 2003; 22:251 (Abstract #1007).
16. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. JAMA 2000; 284:1008-1015.
17. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001;358:1291-1304.
18. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer: N Engl J Med 1997; 336:980-987.
19. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. New Engl J Med 2001; 345:638-646.
20. van de Velde CJ. Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analysis in relation to quality control in a radomized trial. Proc Am Soc Clin Oncol 2002; 21:127a (Abstract #506).
21. Marijnen CAM, Kapiteijn E, van de Velde CJH, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20:817-825.
22. Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55:1311-1320.
23. Beets-Tan RGH, Beets GL, Vliegen RFA, et al. Accuracy of magnetic resonance imaging in prediction of tumor-free resection margin in rectal cancer surgery. Lancet 2001; 357:497-504.
24. Graf W, Dahlberg M, Osman MM, et al. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 1997; 43:133-137.
25. Marijnen CAM, Nagtegaal ID, Kranenbarg EK, et al. No down-staging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19:1976-1984.
26. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing and surgery for rectal cancer. The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17:2396-2402.
27. Rouanet P, Saint Aubert B, Lemanski C, et al. Restorative and Non-restorative surgery for low rectal cancer after high dose radiation. Long term oncologic functional results. Dis Colon Rectum 2002; 45:305-315.
28. Hyams DM, Mamounas EP, Petrelli N, et al. A clinic trial to evaluate the worth of preoperative mutimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R0-3. Dis Colon Rectum 1997; 40:131-139.
29. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998; 40:1067-1075.
30. Grann A, Feng C, Wong D, et al. Pre-op combined modality therapy (CMT) for uT3 rectal cancer. Proc Am Soc Clin Oncol 2000; 19:249a (Abstract #967).
31. Kuvshinoff B, Maghfoor I, Miedema B, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: Are < 1 cm distal margins sufficient? Ann Surg Oncol 2001; 8:163-169.
32. Mehta VK, Cho C, Ford JM, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-flourouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55:132-137.
33. Moore HG, Riedel E, Minsky BD, et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined modality therapy. Ann Surg Oncol 2003; 10:80-85.
34. Grumann MM, Noack EM, Hoffman IA, et al. Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 2001; 233:149-156.
35. Kollmorgen CF, Meagher AP, Pemberton JH, et al. The long term effect of adjuvant postoperative chemoradiotherapy for rectal cancer on bowel function. Ann Surg 1994; 220:676-682.
36. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma: Report from a randomized multicenter trial. Ann Surg 1990; 211:187-195.
37. Roh MS, Petrelli N, Weiand H, et al. Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 2001; 20:123a (Abstract #490).
38. Beets-Tan RGH, Beets GL: Rectal cancer: how accurate can imaging predict the T stage and the circumferential resection margin? Int J Colorec Dis 2003; 18:385-391.
39. Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001; 8:801-806.
40. Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003; 46:448-453.
41. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001; 24:107-112.
42. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000; 48:1075-1080.
43. Read TE, Ogunbiyi OA, Fleshman JW, et al. Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis Colon Rectum 2001; 44:1778-1790.
44. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194:131-136.
45. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46:298-304.
46. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236:75-81.
47. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002; 53:664-674.
48. Luna-Perez P, Segura J, Alvarado I, et al. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 2000; 7:727-731.
49. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19:1779-1786.
50. Esposito G, Pucciarelli S, Alaggio R, et al. p27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001; 8:311-318.
51. Elsaleh H, Robbins P, Joseph D, et al. Can p53 alterations be used to predict tumor response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 2000; 56:239-244.
52. Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 2002; 235:493-498.
53. Schwander O, Bruce HP, Broll R. p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorec Dis 2002; 17:11-19.
54. Saw RPM, Morgan M, Koorey D, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003; 46:192-202.
55. Adell GCE, Zhang H, Evertsson S, et al. Apoptosis in rectal cancer. Prognosis and recurrence after preoperative radiotherapy. Cancer 2001; 91:1870-1875.
56. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52:294-303.
57. Giralt J, Eraso A, Armengol M, et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:1460-1465.
58. Adell G, Zhang H, Jansson A, et al. Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2001; 50:659-663.
59. Fernandez-Martos C, Aparicio J, Bosch C, et al. Preoperative therapy (PT) with oral uracil and tegafur (UFT) and concomitant irradiation (RT) in operable rectal cancer (RC). Preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol 2001; 20:148a (Abstract #590).
60. James RD, Botwood N, Vernon CC, et al. Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study. Ann Oncol 2003; 14:570-573.
61. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al. Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 2002; 21:146a (Abstract #580).
62. Gerard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: yhe Lyon R0-04 phase II trial. J Clin Oncol 2003; 21:1119-1124.
63. Rosenthal DI, Catalano P, Haller DG, et al. ECOG 1297: a phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Proc Am Soc Clin Oncol 2003; 22:273 (Abstract #1094).
64. Aschele C, Friso ML, Pucciarelli S, et al. A phase I-II study of weekly oxaliplatin (OXA) 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2002; 21:132a (Abstract #527).
65. Ngan S, Rischin D, Michael M, et al. A phase I trial of radiotherapy, oxaliplatin and infusional 5-fluorouracil (5FU) for patients with rectal cancer not suitable for curative resection. Proc Am Soc Clin Oncol 2003; 22:291 (Abstract #1169).
66. Eric F, Marc Y, Michel D, et al. A phase I study of 5-fluorouracil continuous infusion (5FU CI), weekly oxaliplatin (OXA) and radiotherapy (RT) in advanced rectal cancer. Proc Am Soc Clin Oncol 2003; 22:344 (Abstract #1381).
67. Carraro S, Roca EL, Cartelli C, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A Phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54:397-402.
68. Freyer G, Bossard N, Romestaing P, et al. Addition of oxaliplatin to continuous infusion fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001; 19:2433-2438.
69. Levine EL, Gollins S, Susnerwala S, et al. Phase I/II study of irinotecan (CPT-11), 5-fluorouracil and concurrent radiotherapy for the treatment of T3-T4 locally advanced inoperable rectal cancer. Proc Am Soc Clin Oncol 2003; 22:345 (Abstract #1384).
70. Mitchell EP, Anne PR, Fry RD, et al. Chemoradiation with CPT-11, 5FU, in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum: a phase I/II study update. Proc Am Soc Clin Oncol 2003; 22:262 (Abstract #1052).
71. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:1512-1521.
72. Dunst J, Reese T, Hoelscher T, et al. Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer. Proc Am Soc Clin Oncol 2003;22:277 (Abstract #1113).
73. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1012).
74. Blackstock AW, Hess S, Chaney S: Oxaliplatin: in vitro evidence of its radiation sensitizing activity - pre-clinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 1999; 45:S253.
75. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5-FU)/Leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life. Proc Am Soc Clin Ocol 2003; 22:252 (Abstract #1009).
76. Rothenberg MA, Oza A, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan. Proc Am Soc Clin Ocol 2003; 22:252 (Abstract #1011).
77. Rothenberg MA, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
78. Landry JC, Rosenthal D, Spitz FR, et al. ECOG 1297: A phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2003; 5:S179.
79. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-3104.
80. Glynne-Jones R, Sebag-Montefiore D, McDonald A, et al. A phase I study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer. Proc Am Soc Clin Oncol 2003; 22:292 (Abstract #1174).
81. Valentini V, Morganti AG, Gambacorta MA, et al. Raltitrexed (Tomudex) and oxaliplatin (Tomox) preliminary results of a phase II study of chemoradiation with preoperative treatment of stage II/III resectable rectal cancer. Proc Am Soc Clin Oncol 2002; 21:151a (Abstract #603).
82. Fernandez-Martos C, Aparicio J, Bosch C, et al. Combined modality treatment with oxaliplatin, oral uracil and tegafur (UFT) and concomitant irradiation (RT) in rectal cancer. A dose finding study. Proc Am Soc Clin Ocol 2003; 22:322 (Abstract #1293).
83. Chau I, Cunningham D, Tait D, et al. Twelve weeks of neoadjuvant capecitabine (cap) and oxaliplatin (ox) followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumor regression and rapid symptomatic relief. Proc Am Soc Clin Oncol 2003; 22:271 (Abstract #1087).
84. Calvo FA, Serrano F, Gomez-Espi M, et al. Induction oxaliplatin + 5-FU improves further the incidence of pT0 downstaged surgical specimens in > cT3 rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2003; 57:S178.
85. Klautke G, Kirchner R, Hopt U, et al. Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 2001; 20:140a (Abstract #555).
86. Mitchell EP, Anne P, Fry R, et al. Combined modality therapy of locally advanced or recurrent adenocarcinoma of the rectum: report of a phase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT). Proc Am Soc Clin Oncol 2001; 20:131a (Abstract #519).